Zobrazeno 1 - 2
of 2
pro vyhledávání: '"therapeutic use [4-Aminopyridine]"'
Autor:
José M. Serratosa, Kathleen M. Gorman, Dragan Marjanovic, Adrian Binelli, Niklas Schwarz, Kirsten Torge, Guido Rubboli, Monika Fudali, Harshad Pannikkaveettil Ashraf, Sanjay M. Sisodiya, Ulrike B. S. Hedrich, Matthis Synofzik, Mary D. King, Lily C. Wong-Kisiel, Pu Yan, Bruria Ben Zeev, Pedro Martínez-Ulloa, Holger Lerche, Michal Tzadok, Stephan Lauxmann, Christian Bosselmann, Thomas Bast, Markus Wolff, Florian Lutz, Nicholas M. Allen
Publikováno v:
Science translational medicine 13(609), eaaz4957 (2021). doi:10.1126/scitranslmed.aaz4957
Developmental and epileptic encephalopathies are devastating disorders characterized by epilepsy, intellectual disability, and other neuropsychiatric symptoms, for which available treatments are largely ineffective. Following a precision medicine app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afb3cf4423213ffbf936fc3d43041809
https://doi.org/10.1126/scitranslmed.aaz4957
https://doi.org/10.1126/scitranslmed.aaz4957
Autor:
Heike Jacobi, Martina Minnerop, Julian Teufel, Klaus Jahn, L. Schoels, Matthis Synofzik, Ilaria Giordano, Thomas Klockgether, M Bogdanow
Publikováno v:
Journal of neurology 260(8), 2175-2176 (2013). doi:10.1007/s00415-013-7029-5
4-Aminopyridine (4-AP) is a reversible blocker of voltagegated potassium channels. Its slow release form has been approved for symptomatic treatment of gait disorder in multiple sclerosis [2]. In a number of small studies, 4-AP and the related compou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e97216173c58940a55172ba2472f332b
https://pub.dzne.de/record/137011
https://pub.dzne.de/record/137011
